Rajeev Saggar
Pulmonary Disease · Phoenix, AZNPI 1225230543
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Boehringer Ingelheim at 32.2% of the total. Reporting peaked in 2019 at $145,631 and has fallen 100.0% since, to $33 in 2024. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $627.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$52K
- United Therapeutics Corporation$31K
- Bayer$29K
- Genentech USA, Inc.$25K
- Actelion Pharmaceuticals US, Inc.$20K
- Neuronetics, Inc.$1K
- plus $2K from 24 others
Across 3 payments — averaging $19,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$57K
What the payments were for
- Consulting fees$51,97032%
- Speaking & faculty fees$78,49349%
- Travel & lodging$23,55615%
- Food & beverage$7,1094%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $51,945 |
| United Therapeutics Corporation | 45 | $31,192 |
| Bayer | 41 | $29,395 |
| Genentech USA, Inc. | 29 | $24,643 |
| Actelion Pharmaceuticals US, Inc. | 27 | $20,257 |
| Neuronetics, Inc. | 6 | $1,250 |
| Pulmonx Corporation | 7 | $706 |
| Janssen Research & Development, LLC | 3 | $339 |
| Grifols USA, LLC | 11 | $279 |
| Sandoz | 7 | $258 |
| Veran Medical Technologies, Inc. | 2 | $164 |
| Gilead | 4 | $133 |
| Philips North America LLC | 5 | $112 |
| Electromed, Inc. | 8 | $81 |
| Johnson & Johnson(2 entities) | 4 | $58 |
| Merck | 4 | $56 |
| AbbVie | 3 | $38 |
| Vapotherm Inc | 1 | $28 |
| GSK | 2 | $27 |
| Astellas Pharma US Inc | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Biosense Webster, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| AstraZeneca | 1 | $14 |
| PARI Respiratory Equipment, Inc. | 1 | $14 |
| Pinnacle Biologics, Inc | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$46,794
- Adempas$28,546
- Esbriet$24,448
- NONE$14,400
- ORENITRAM$7,966
- TYVASO$7,654
- UPTRAVI$6,422
- NEUROSTAR TMS THERAPY$927
- Pulmonx Endobronchial Valve EBV$502
- OPSUMIT$416
- REMODULIN$221
- Prolastin-C$148
- Spin$100
How this compares
$161,139 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
- Bhuvin BuddhdevPhoenix$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.